cells

One of the two major classes of lymphocytes, B lymphocytes are white blood cells of the immune system that are derived from the bone marrow and spleen.

Cell Type:

B cell

Tissue Origin:

blood

Species:

human

GO TO SHOP

Research Area:

Immunotherapy / Hematology

Cell Characteristics:

Suspension

Recommended Media

TheraPEAK® X-VIVO®

TheraPEAK® X-VIVO® Media is a high-performing media series providing nutritionally adequate and balanced environments for a variety of hematopoietic cells including:

T Cells
CAR-T cells
Peripheral blood lymphocytes (PBL)
Tumor infiltrating lymphocytes (TIL)
Human monocytes and macrophages
Lymphokine-activated killer cells (LAK)
Hematopoietic stem cells (HSCs)
Dendritic cells (DCs)

Our scalable media are widely cited in scientific publications and proven to reliably work in many cell therapy applications around the world, from research stages to clinical trials to FDA-approved cell therapies. TheraPEAK® Products are manufactured according to GMP standards and can be safely and confidently used in your clinical processes. Our manufacturing sites are FDA registered with an ISO 13485 certified quality management system.

There are two main versions of this media.

TheraPEAK® X-VIVO® 10 Media are optimized for slower growing, less mature cells, such as hematopoietic stem cells

TheraPEAK® X-VIVO® 15 Media are most appropriate for rapidly growing cells, specifically cells of the immune system

TheraPEAK® X-VIVO® 10 Media and 15 Media are also available with recombinant transferrin instead of native human transferrin

Please note: X-VIVO™ 20 is currently available as an RUO grade catalog item.

Storage: 2-8C, protect from light.

Catalog Offerings:

TheraPEAK® X-VIVO® Medium with native transferrin
Cat. No. NA	Cat.CCat. No. EU	Product	Size
BP04-743Q	BEBP04-743Q	TheraPEAK® X-VIVO® 10 Medium without gentamicin and phenol red, contains native transferrin	1 L bottle
BP04-744Q	BEBP04-744Q	TheraPEAK® X-VIVO® 15 Medium with L-glutamine, without gentamicin and phenol red, contains native transferrin	1 L bottle
08-879H 08-879P1	BE08-879H BE08-879P1	TheraPEAK® X-VIVO® 15 Medium with L-glutamine, without gentamicin and phenol red, contains native transferrin	5 L bag 1 L bag
TheraPEAK™ X-VIVO™ Medium with recombinant transferrin
Cat. No. NA	Cat. No. EU	Product	Size
N/A	BEBP02-055Q	TheraPEAK® X-VIVO® 10 Medium with L-glutamine, without gentamicin or phenol red, contains recombinant transferrin	1 L bottle
BP02-054Q BP02-054P1	BEBP02-054Q BEBP02-054P1	TheraPEAK® X-VIVO® 15 Medium with L-glutamine, without gentamicin and phenol red, contains recombinant transferrin	1 L bottle 1 L bag

Lymphocyte Growth Medium-3

LGM-3 is a serum-free medium for lymphocyte and dendritic cell growth

Transfection Information

Lonza Optimized Protocol
Optimization Guideline

Filter:

The table below shows data for the cell type and Nucleofector™ Platform selected. Those data are either based on Lonza Optimized Protocols or on results shared from customers who performed an optimization based on our guidelines. In case no data are shown for the selected Nucleofector™ Platform, please take a look at our optimization strategy to get further guidance on how to easily determine optimal Nucleofection conditions yourself.

Kit	Program	Cells	Efficiency	Viable Cells	Substrate		Format	Platform
P3	EO-117-AA	1e6	30-39%	70%	Plasmid (general)	0.4 µg	20 µl	384-well
P3	EO-117-AA	1e6	30-39%	70%	Plasmid (general)	0.4 µg	20 µl	384-well
B cell, human	U-015	1e6	25-47%	84-92%	Plasmid (general)	5 µg	100 µl	I/II/2b
P3	96-EO-117	1e6	22-34%	63-77%	Plasmid (general)	0.4 µg	20 µl	96-well
P3	EO-117	1e6	22-34%	63-77%	Plasmid (general)	0.4 µg	20 µl	4D X-Unit

Citations (29)

Peptide-mediated delivery of CRISPR enzymes for the efficient editing of primary human lymphocytes

Categories:

Primary Cells and Media, Serum-free and Speciality Media, Transfection, Cell Lines and Primary Cancer Cells

Authors:

Foss DV, Muldoon JJ, Nguyen DN, Carr D, Sahu SU, Hunsinger JM, Wyman SK, Krishnappa N, Mendonsa R, Schanzer EV, Shy BR, Vykunta VS, Allain V, Li Z, Marson A, Eyquem J, Wilson RC

In:

Nat Biomed Eng (2023) 5: 647-660

Highly efficient CRISPR-Cas9-mediated geneknockout in primary human B cells forfunctional genetic studies of Epstein-Barrvirus infection

Categories:

Transfection

Authors:

Akidil E, Albanese M, Buschle A, Ruhle A, Pich D, Keppler OT, Hammerschmidt W.

In:

PLoS Pathog (2021) 17(4): e1009117

HIV-specific humoral immune responses by CRISPR/Cas9-edited B cells.

Categories:

Transfection

Authors:

Hartweger H, McGuire AT, Horning M, Taylor JJ, Dosenovic P, Yost D, Gazumyan A, Seaman MS, Stamatatos L, Jankovic M, Nussenzweig MC.

In:

J Exp Med (2019) 216 (6): 1301-1310

CRISPR-Mediated Editing of the B Cell Receptor in Primary Human B Cells.

Categories:

Primary Cells and Media, Transfection

Authors:

Greiner V, Bou Puerto R, Liu S, Herbel C, Carmona EM, Goldberg MS.

In:

iScience (2019) 12: 369-378

RNAi Transfection Optimized in Primary Naïve B Cells for the Targeted Analysis of Human Plasma Cell Differentiation

Categories:

Transfection

Authors:

Shih T, De S, Barnes BJ

In:

Frontiers in Immunology (2019) 10: 1652

Sensitive, multiplex and direct quantification of RNA sequences using a modified RASL assay.

Categories:

Classical Media and Reagents, Serum-free and Speciality Media

Authors:

Larman HB, Scott ER, Wogan M, Oliveira G, Torkamani A, Schultz PG

In:

Nucleic Acids Res (2014) 42(4): 9146-57

Alterations in cholesterol metabolism restrict HIV-1 trans infection in nonprogressors

Categories:

Transfection

Authors:

Rappocciolo G, Jais M, Piazza P, Reinhart TA, Berendam SJ, Garcia-Exposito L, Gupta P, Rinaldo CR

In:

mBio (2014) 5(3): 1-11

Congenital B cell lymphocytosis explained by novel germline CARD11 mutations.

Categories:

Transfection

Authors:

Snow AL, Xiao W, Stinson JR, Lu W, Chaigne-Delalande B, Zheng L, Pittaluga S, Matthews HF, Schmitz R, Jhavar S, Kuchen S, Kardava L, Wang W, Lamborn IT, Jing H, Raffeld M, Moir S, Fleisher TA, Staudt LM, Su HC, Lenardo MJ.

In:

J Exp Med (2012) 209(12): 2247-2261

Attenuation of HIV-associated human B cell exhaustion by siRNA downregulation of inhibitory receptors.

Categories:

Transfection

Authors:

Kardava L, Moir S, Wang W, Ho J, Buckner CM, Posada JG, O'Shea MA, Roby G, Chen J, Sohn HW, Chun TW, Pierce SK, Fauci AS.

In:

J Clin Invest (2011) 121(7): 2614-24

Selection of the alternative exon 1 from the cd5 gene down-regulates membrane level of the protein in B lymphocytes

Categories:

Transfection

Authors:

Garaud S, Le Dantec C, Berthou C, Lydyard PM, Youinou P, Renaudineau Y

In:

J Immunol (2008) 181(3): 2010-8

RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma

Categories:

Transfection

Authors:

Mason NJ, Coughlin CM, Overley B, Cohen JN, Mitchell EL, Colligon TA, Clifford CA, Zurbriggen A, Sorenmo KU, Vonderheide RH

In:

Gene Ther (2008) 15(13): 955-65

Nuclear CD40 interacts with c-Rel and enhances proliferation in aggressive B cell Lymphoma

Categories:

Transfection

Authors:

Zhou HJ, Pham LV, Tamayo AT, Lin-Lee YC, Fu L, Yoshimura LC, Ford RJ

In:

Blood (2007) 110(6): 2121-7

Efficient nucleofection of primary human B cells and B-CLL cells induces apoptosis, which depends on the microenvironment and on the structure of transfected nucleic acids

Categories:

Transfection

Authors:

Seiffert M, Stilgenbauer S, Döhner H, Lichter P

In:

Leukemia (2007) 21(9): 1977-83

Decreased expression of Kruppel-like factors in memory B cells induces the rapid response typical of secondary antibody responses

Categories:

Transfection

Authors:

Good KL, Tangye SG

In:

Proc Natl Acad Sci USA (2007) 104(33): 13420-5

TACI regulates IgA production by APRIL in collaboration with HSPG

Categories:

Transfection

Authors:

Sakurai D, Hase H, Kanno Y, Kojima H, Okumura K, Kobata T

In:

Blood (2007) 109(7): 2961-7

c-Abl Expression in Chronic Lymphocytic Leukemia Cells: Clinical and Therapeutic Implications

Categories:

Transfection

Authors:

Lin K, Glenn MA, Harris RJ, Duckworth AD, Dennett S, Cawley JC, Zuzel M, Slupsky JR

In:

Cancer Res (2006) 66(15): 7801-9

Nuclear localization in the biology of the CD40 receptor in normal and neoplastic human B lymphocytes

Categories:

Transfection

Authors:

Lin-Lee YC, Pham LV, Tamayo AT, Fu L, Zhou HJ, Yoshimura LC, Decker GL, Ford RJ

In:

J Biol Chem (2006) 281(27): 18878-87

High Mda-7 expression promotes malignant cell survival and p38 MAP kinase activation in chronic lymphocytic leukemia

Categories:

Transfection

Authors:

Sainz-Perez A, Gary-Gouy H, Portier A, Davi F, Merle-Beral H, Galanaud P, Dalloul A

In:

Leukemia (2006) 20(3): 498-504

Regulation of the germinal center gene program by interferon (IFN) regulatory factor 8/IFN consensus sequence-binding protein

Categories:

Transfection

Authors:

Lee CH, Melchers M, Wang H, Torrey TA, Slota R, Qi CF, Kim JY, Lugar P, Kong HJ, Farrington L, van der Zouwen B, Zhou JX, Lougaris V, Lipsky PE, Grammer AC and Morse HC 3rd

In:

J Exp Med (2006) 203(1): 63-72

Constitutive NF-kappaB and NFAT activation in aggressive B-cell lymphomas synergistically activates the CD154 gene and maintains lymphoma cell survival

Categories:

Transfection

Authors:

Pham LV, Tamayo AT, Yoshimura LC, Lin-Lee YC and Ford RJ

In:

Blood (2005) 106(12): 3940-3947

Haploinsufficiency, rather than the effect of an excessive production of soluble CD95 (CD95TM), is the basis for ALPS Ia in a family with duplicated 3' splice site AG in CD95 intron 5 on one allele

Categories:

Transfection

Authors:

Roesler J, Izquierdo JM, Ryser M, Rosen-Wolff A, Gahr M, Valcarcel J, Lenardo MJ and Zheng L

In:

Blood (2005) 106(5): 1652-1659

Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells

Categories:

Transfection

Authors:

Gorgun G, Holderried TA, Zahrieh D, Neuberg D and Gribben JG

In:

J Clin Invest (2005) 115(7): 1797-1805

Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo

Categories:

Transfection

Authors:

Laichalk LL and Thorley-Lawson DA

In:

J Virol (2005) 79(2): 1296-1307

E47, IRF-4 and PU.1 synergize to induce B cell-specific activation of the Class II Transactivator promoter III (CIITA-PIII)

Categories:

Transfection

Authors:

Van der Stoep N, Quinten E, Rezende MM and Van den Elsen PJ

In:

Blood (2004) 104(9): 2849-2857

Jak3-independent trafficking of the common gamma chain receptor subunit: chaperone function of Jaks revisited

Categories:

Transfection

Authors:

Hofmann SR, Lam AQ, Frank S, Zhou YJ, Ramos HL, Kanno Y, Agnello D, Youle RJ and O'Shea JJ

In:

Mol Cell Biol (2004) 24(11): 5039-5049

New non-viral method for gene transfer into primary cells

Categories:

Transfection

Authors:

Gresch O, Engel FB, Nesic D, Tran TT, England HM, Hickman ES, Korner I, Gan L, Chen S, Castro-Obregon S, Hammermann R, Wolf J, Muller-Hartmann H, Nix M, Siebenkotten G, Kraus G and Lun K

In:

Methods (2004) 33(2): 151-163

RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy

Categories:

Transfection

Authors:

Coughlin CM, Vance BA, Grupp SA and Vonderheide RH

In:

Blood (2004) 103: 2046-2054

NF-kappaB regulates the expression of human complement receptor 2 gene

Categories:

Transfection

Authors:

Tolnay M, Vereshchagina LA and Tsokos GC

In:

J Immunol (2002) 169: 6236-6243

RGS13 regulates germinal center B lymphocytes responsiveness to CXC chemokine ligand (CXCL)12 and CXCL13

Categories:

Transfection

Authors:

Shi GX, Harrison K, Wilson GL, Moratz C and Kehrl JH

In:

J Immunol (2002) 169(5): 2507-2515

+ Show All

B cell, human

Recommended Media

Transfection Information

Citations (29)